Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Day One Biopharmaceuticals (DAWN)
NASDAQ:DAWN
RESEARCH TOOLSreports
Day One Biopharmaceuticals (DAWN) Stock Price & Analysis
163 Followers
DAWN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.67 - $17.85
Previous Close$16.64
Volume3.79M
Average Volume (3M)800.93K
Market Cap
$1.45B
Enterprise Value$1.05B
Total Cash (Recent Filing)$405.54M
Total Debt (Recent Filing)$514.00K
Price to Earnings (P/E)-7.0
Beta-0.36
Next Earnings
May 09, 2024EPS Estimate
-$0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.36
Shares Outstanding87,384,856
10 Day Avg. Volume1,874,913
30 Day Avg. Volume800,932
Standard Deviation0.36
R-Squared0.05
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)4.20
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue287.49
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-8.26
Forecast
1Y Price Target
$36.56Price Target Upside176.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Day One Biopharmaceuticals News
PremiumCompany Announcements
Day One Biopharmaceuticals Achieves FDA Approval and Rare Voucher
Bulls Say, Bears Say
Bulls Say
Commercial StrategyDay One Biopharmaceuticals' established closed distribution model with specialty pharmacy partners showcases their readiness for a successful commercial launch.
Market PotentialThe broad label approval for Ojemda (tovorafenib), covering patients from 6 months old, coupled with the absence of restrictive labeling, suggests a large potential market, enhancing the drug's commercial prospects.
Regulatory MilestoneThe FDA approval of Ojemda (tovorafenib) for pediatric low-grade glioma with BRAF alterations represents a significant regulatory milestone, creating opportunities for widespread adoption and market penetration.
Bears Say
Drug Label ConcernsThe approved label came with some surprises, which could impact the drug's uptake and physician's prescribing decisions.
Financial Performance4Q23 EPS of -$0.63 came in below consensus of -$0.57, likely driven by higher R&D and SG&A expenses.
Market Adoption RisksRisks such as failure to gain FDA approval, limited market adoption post-approval, or adverse events disrupting trial progress could impact the stock negatively.
---
Ownership Overview
56.94% Insiders
20.07% Mutual Funds
11.99% Other Institutional Investors
11.00% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DAWN FAQ
What was Day One Biopharmaceuticals’s price range in the past 12 months?
Day One Biopharmaceuticals lowest stock price was $9.67 and its highest was $17.85 in the past 12 months.
What is Day One Biopharmaceuticals’s market cap?
Currently, no data Available
When is Day One Biopharmaceuticals’s upcoming earnings report date?
Day One Biopharmaceuticals’s upcoming earnings report date is May 09, 2024 which is in 13 days.
How were Day One Biopharmaceuticals’s earnings last quarter?
Day One Biopharmaceuticals released its earnings results on Feb 26, 2024. The company reported -$0.63 earnings per share for the quarter, missing the consensus estimate of -$0.574 by -$0.056.
Is Day One Biopharmaceuticals overvalued?
According to Wall Street analysts Day One Biopharmaceuticals’s price is currently Undervalued.
Does Day One Biopharmaceuticals pay dividends?
Day One Biopharmaceuticals does not currently pay dividends.
What is Day One Biopharmaceuticals’s EPS estimate?
Day One Biopharmaceuticals’s EPS estimate is -$0.66.
How many shares outstanding does Day One Biopharmaceuticals have?
Day One Biopharmaceuticals has 87,384,860 shares outstanding.
What happened to Day One Biopharmaceuticals’s price movement after its last earnings report?
Day One Biopharmaceuticals reported an EPS of -$0.63 in its last earnings report, missing expectations of -$0.574. Following the earnings report the stock price went up 11.054%.
Which hedge fund is a major shareholder of Day One Biopharmaceuticals?
Among the largest hedge funds holding Day One Biopharmaceuticals’s share is RA Capital Management. It holds Day One Biopharmaceuticals’s shares valued at 114M.
---
Day One Biopharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$36.56 (176.76% Upside)
$36.56 (176.76% Upside)
Blogger Sentiment
Bullish
DAWN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 518.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.4%
Last 30 Days ▲ 15.1%
Last 30 Days ▲ 15.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.79%
12-Months-Change
Fundamentals
Return on Equity
-55.68%
Trailing 12-Months
Asset Growth
7.73%
Trailing 12-Months
Company Description
Day One Biopharmaceuticals
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The lead product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
---
DAWN Stock 12 Months Forecast
Average Price Target
$36.56
▲(176.76% Upside)
Technical Analysis
Galectin Therapeutics
―
Gritstone Oncology
―
Helius Medical Technologies
―
Mersana Therapeutics
―
Best Analysts Covering DAWN
1 Year
1 Year Success Rate
8/13 ratings generated profit
1 Year Average Return
-4.35%
reiterated a buy rating 3 days ago
Copying Soumit Roy's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of -4.35% per trade.
---